PTK2 and chronic myelogenous leukemia, BCR-ABL1 positive: However, there are reports of imatinib-resistant Ph+ CML tumour cells undergoing a mesenchymal-like conversion associated with increased levels of FAK tyrosine phosphorylation and increased adherence and invasiveness26.